

Canakinumab

Cat. No.:	HY-108810
CAS No.:	914613-48-2
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Canakinumab (ACZ885) is a recombinant human anti-IL-1 β monoclonal antibody. Canakinumab shows IC ₅₀ values of 43.6 and 40.8 pM for human and marmoset IL-1 β , respectively. The mode of action of canakinumab is based on the neutralization of IL-1 β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin ^{[1][2]} .
IC₅₀ & Target	IC ₅₀ : 43.6 pM (human IL-1 β), 40.8 pM (marmoset IL-1 β) ^[2]
In Vitro	Canakinumab (0-7 nM) dose dependently represses IL-6 production in marmoset peripheral blood mononuclear cells with IC ₅₀ s of 43.6 and 40.8 pM for human and marmoset IL-1 β ^[2] . Canakinumab effectively competes with IL-1RI and IL-1RII for binding to IL-1 β ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Dhimolea E. Canakinumab. MAbs. Epub 2010 Jan 15.

[2]. Rondeau JM, et al. The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1 β . MAbs. 2015;7(6):1151-60.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA